Research map: Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience

Back to the article

Papers in this map

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer · Martin Reck · 2016 · 10309 citations · Cited by this paper
  2. First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study) · R. Descourt · 2023 · 29 citations · Related
  3. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer · Leena Gandhi · 2018 · 6765 citations · Cited by this paper
  4. Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · 2026 · Related
  5. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer · Luis G Paz-Ares · 2018 · 3711 citations · Cited by this paper
  6. Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences · 2026 · Related
  7. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial · Tony S.K. Mok · 2019 · 3390 citations · Cited by this paper
  8. Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice · 2026 · Related
  9. Cancer statistics, 2025 · Rebecca L. Siegel · 2025 · 2992 citations · Cited by this paper
  10. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · 2026 · Related
  11. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% · Martin Reck · 2021 · 1185 citations · Cited by this paper
  12. IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · 2026 · Related
  13. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study · Marina Chiara Garassino · 2023 · 725 citations · Cited by this paper
  14. Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · 2026 · Related
  15. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study · Silvia Novello · 2023 · 563 citations · Cited by this paper
  16. Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions · 2026 · Related
  17. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions · Mina S. Sedrak · 2020 · 493 citations · Cited by this paper
  18. PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017–2021 · 2025 · Related
  19. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 · Delvys Rodríguez‐Abreu · 2021 · 429 citations · Cited by this paper
  20. Real-World Outcomes of Pembrolizumab in Advanced Melanoma by Age and Sex: A National Population-Based Study · 2025 · Related
  21. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN · Jialin Zhou · 2024 · 372 citations · Cited by this paper
  22. Real-world Data for Clinical Evidence Generation in Oncology · Sean Khozin · 2017 · 368 citations · Cited by this paper
  23. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression · Esther Aguilar · 2019 · 348 citations · Cited by this paper
  24. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study · Gilberto de Castro · 2022 · 345 citations · Cited by this paper
  25. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment · Yaser Alduais · 2023 · 340 citations · Cited by this paper
  26. Real-world data: towards achieving the achievable in cancer care · Christopher M. Booth · 2019 · 331 citations · Cited by this paper
  27. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond · Lee H. Pai-Scherf · 2017 · 297 citations · Cited by this paper
  28. From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients · H‐G Eichler · 2015 · 194 citations · Cited by this paper
  29. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153) · David Robert Spigel · 2019 · 190 citations · Cited by this paper
  30. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival · Ana Casal-Mouriño · 2021 · 184 citations · Cited by this paper
  31. Real-World Evidence in Oncology: Opportunities and Limitations · Massimo Di Maïo · 2019 · 172 citations · Cited by this paper
  32. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer · Caroline A. Nebhan · 2021 · 161 citations · Cited by this paper
  33. Lung Cancer Screening in Asia: An Expert Consensus Report · David Chi-Leung Lam · 2023 · 146 citations · Cited by this paper
  34. Lung Cancer Screening in the US, 2022 · Priti Bandi · 2024 · 136 citations · Cited by this paper
  35. Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies · Didier Debieuvre · 2022 · 84 citations · Cited by this paper
  36. The Expanding Role of Real-World Evidence Trials in Health Care Decision Making · David Charles Klonoff · 2019 · 80 citations · Cited by this paper
  37. Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis · Tianhao Zhu · 2020 · 80 citations · Cited by this paper
  38. Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy · Teja Voruganti · 2023 · 77 citations · Cited by this paper
  39. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data · Elizabeth Dudnik · 2021 · 72 citations · Cited by this paper

Source: OpenAlex (CC0)